|
タキザワ マキコ
TAKIZAWA Makiko
滝沢 牧子 所属 埼玉医科大学 医学部 総合医療センター 医療安全管理学 職種 教授 |
|
| 論文種別 | 学術雑誌(原著) |
| 言語種別 | 英語 |
| 査読の有無 | 査読あり |
| 表題 | IL17A and IL23R gene polymorphisms affect the clinical features and prognosis of patients with multiple myeloma. |
| 掲載誌名 | 正式名：Hematological oncology |
| 掲載区分 | 国外 |
| 巻・号・頁 | 36(1),196-201頁 |
| 著者・共著者 | Tetsuhiro Kasamatsu,Mari Kimoto,Noriyuki Takahashi,Yusuke Minato,Nanami Gotoh,Makiko Takizawa,Morio Matsumoto,Morio Sawamura,Akihiko Yokohama,Hiroshi Handa,Norifumi Tsukamoto,Takayuki Saitoh,Hirokazu Murakami |
| 発行年月 | 2018/02 |
| 概要 | Single nucleotide polymorphisms (SNPs) in interleukin 17 (IL17A) and IL-23 receptor (IL23R) are involved in the pathogenesis of many cancers and autoimmune diseases. We investigated the influence of IL17A and IL23R SNPs on the risk of developing multiple myeloma (MM) and its clinical features. We obtained genomic DNA from 120 patients with MM and 201 healthy controls and detected IL17A -197 G/A (rs2275913) and IL23R H3Q (rs1884444) genotypes using the polymerase chain reaction-restriction fragment length polymorphism method. There were no significant differences in the genotype and allele frequencies of IL17A -197 G/A and IL23R H3Q between the controls and patients with MM. Compared with the GG and GA genotypes, the IL17A AA genotype was significantly associated with lower hemoglobin levels. The IL23R HH genotype was significantly associated with higher frequency of bone lesions and plasmacytoma than the HQ and QQ genotypes. We observed significant differences in overall survival (OS) between patients treated with thalidomide and/or bortezomib and those treated conventionally. Therefore, we also examined the effect of IL17A and IL23R polymorphisms on the clinical variables and OS in patients treated with thalidomide and/or bortezomib. We observed that the IL23R HH genotype was significantly associated with poor survival compared with the QH and HH genotypes in these patients. Our findings indicate that IL17A -197 G/A and IL23R H3Q are not associated with susceptibility to MM. However, IL-17 and IL-23R polymorphisms may affect severity, bone lesions, and extra-medullary disease in patients with MM. Moreover, IL23R polymorphisms may contribute to poor prognosis in patients with MM treated with thalidomide and/or bortezomib. |
| DOI | 10.1002/hon.2469 |
| PMID | 28786198 |